By

admin
Exactis study, Analysis of the genomic landscape, ALK, NSCLC
Authors: Jordi Rodon, Jean-Charles Soria, Raanan Berger, Wilson H. Miller, Eitan Rubin, Aleksandra Kugel, Apostolia Tsimberidou, Pierre Saintigny, Aliza Ackerstein, Irene Braña, Yohann Loriot, Mohammad Afshar, Vincent Miller, Fanny Wunder, Catherine Bresson, Jean-François Martini, Jacques Raynaud, John Mendelsohn, Gerald Batist, Amir Onn, Josep Tabernero, Richard L. Schilsky, Vladimir Lazar, J. Jack Lee & Razelle Kurzrock...
Read More
We are pleased to share an article on Precision Oncology and the Exactis PMT initiative appearing on www.personalhealthnews.ca, and printed in the April 2019 edition of Maclean’s Magazine, as part of a Mediaplanet special interest “Advancements in Cancer Care & Rare Disease” campaign. “Precision oncology is about selecting the right drug or treatment for the...
Read More
Exactis Innovation is pleased to formally announce the launch of the Exactis Innovation Investigator-Initiated Trial (IIT) Grant Competition. In alignment with the Exactis Mission to accelerate precision oncology by matching specific molecular or clinical profiles to novel treatments available through clinical trials, the Exactis IIT Grant Competition will provide $CDN 1 million to a team...
Read More
MRM Proteomics Inc. is partnering with Exactis Innovation to develop and validate a clinical proteomic test that will provide clinicians and scientists with the ability to identify immune signatures and tumour mutation profiles to better match patients with the most effective treatments. The novel diagnostic test will be the first immuno-MALDI test to measure the...
Read More
At risk cancer patients across Canada may now be able to have their tumors molecularly profiled using next-generation sequencing (NGS) as part of a national effort to expedite enrollments in clinical trials. Led by Exactis Innovation, a non-profit organization focused on accelerating precision cancer research and access to targeted therapies, the program’s NGS-based studies will be standardized...
Read More
Since November 2015 (when the first PMT participant signed the PMT informed consent form) you have helped us expand PMT throughout Canada and have recruited nearly 1,500 participants to name only a few milestones! The graphic below outlines some of the biggest feats we’ve been able to accomplish together in the past 2 years. Thank...
Read More
Exactis, study
Authors: Miguel Alcaide, Stephen Yu, Jordan Davidson, Marco Albuquerque, Kevin Bushell, Daniel Fornika, Sarah Arthur, Bruno M. Grande, Suzan McNamara, Mathilde Couetoux du Tertre, Gerald Batist, David G. Huntsman, Luca Cavallone, Adriana Aguilar, Mark Basik, Nathalie A. Johnson, Rebecca J. Deyell, S. Rod Rassekh, and Ryan D. Morin1 Abstract Ultrasensitive methods for rare allele detection...
Read More
Five major Quebec cancer treatment centres are partnering with Montreal-based Exactis Innovation to build a coordinated network to match cancer patients to clinical trials based on the characteristics of their tumour through an innovative digital registry. The “Personalize My Treatment” (PMT) digital registry addresses the challenge of recruiting and matching cancer patients who have had their cancer molecularly...
Read More
At an announcement made earlier today, Merck confirmed its commitment to research and innovation in oncology by contributing a total of $2 million to the Exactis Innovation ‘Personalize My Treatment’ (PMT) initiative. In addition, the Cancer Research Society (CRS) and the New Brunswick Health Research Foundation (NBHRF) will also contribute $1 million each to help...
Read More
At the 6th Annual National Conference to Defeat Cancer, organized by Coalition Priorité Cancer, Merck Canada reinforced the company’s continued commitment to the Quebec life sciences research innovation sector by announcing a $2-million grant to the Quebec – Consortium de recherche en oncologie clinique (Q-CROC).
Read More
1 2 3 4